Mazdutide: What Current Dual-Agonist Research Is Exploring

Introduction

In the quest for effective treatments against obesity and type 2 diabetes mellitus (T2DM), mazdutide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors, has emerged as a promising candidate. The nuances of this peptide, encompassing its efficacy, safety, and potential applications, have been the focus of several recent studies.

Mechanism of Action

Mazdutide operates by simultaneously activating the GLP-1 and glucagon receptors. This dual activation fosters an increased energy expenditure and appetite suppression, both critical pathways in reducing weight and managing glucose levels in patients with T2DM. The GLP-1 receptor activation predominantly influences glucose-dependent insulin secretion, while simultaneous glucagon receptor activation enhances energy expenditure by promoting lipolysis and improving metabolic rate [Kamrul-Hasan et al., 2026].

Phase 1 and 2 Studies

Initial Findings

Early trials of mazdutide focused on determining the maximum tolerated dose and preliminary efficacy in weight reduction among overweight or obese adults. Bhattachar et al. (2025) conducted a Phase 1 study revealing that doses up to 16 mg led to significant weight reductions of up to 20% over a 20-week period. These trials demonstrated safety profiles characterized by mildly increased gastrointestinal adverse events, including nausea, diarrhea, and vomiting [Bhattachar et al., 2025].

US-Based Phase 2 Trials

In a Phase 2 trial conducted in the United States, without participants having T2DM, mazdutide confirmed its efficacy in reducing body weight at varying doses from 3 mg to 16 mg. The greatest efficacy was observed at the 16 mg dose, which achieved a mean weight reduction of over 20% [Hsia et al., 2026].

Phase 3 Clinical Trials

The GLORY-2 Study

Conducted among Chinese adults with a BMI of 30 kg/m² or greater, the GLORY-2 trial assessed the effects of a 9 mg once-weekly dosing over 60 weeks. Participants experienced a mean weight reduction of 16.65% compared to a mere 1.50% in the placebo group, highlighting a notable treatment effect [Gao et al., 2026].

DREAMS-3 Trial

The DREAMS-3 study aimed at directly comparing mazdutide to semaglutide in individuals with T2DM and obesity. Preliminary data indicated mazdutide was promising in achieving the co-primary outcomes of significant HbA1c and body weight reductions over 32 weeks. However, final results are yet to be fully published [Luo et al., 2026].

Comparative Analysis

Mazdutide's efficacy and safety have been evaluated against other glucagon receptor agonists such as retatrutide and cotadutide. Although retatrutide showed superior weight reduction, mazdutide maintained a more favorable safety profile with fewer discontinuations due to adverse effects [Abulehia et al., 2026].

Dosing Protocol

Mazdutide enjoys one of the flexible dosing regimens. Typically, it begins with lower doses of 3–4 mg in initial treatment phases, gradually escalating especially in Western settings up to 16 mg, based on tolerability and targeted weight reduction goals [Hsia et al., 2026; Bhattachar et al., 2025].

Recommended Protocol

• Induction Phase: Start at 3–4 mg weekly for initial tolerance.
• Escalation Phase: Increase to 9 mg as intermediate dosing over 12–16 weeks.
• Maintenance Phase: Achieve up to 16 mg weekly upon patient response and tolerability.

Key Takeaways

Mazdutide represents a novel approach in addressing obesity and type 2 diabetes, boasting significant weight reduction capabilities and potential benefits in metabolic health. However, as with any novel therapeutic, continued research is warranted, particularly to explore long-term cardiovascular outcomes and applicability in diverse populations.

Ask PepBot for your personalized protocol.